A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors-Reference-Cited by-同舟云学术

A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors

Published:2020-04-15 Issue:8 Volume:126 Page:1749-1757
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Santana Victor M.¹^ORCID,Sahr Natasha²,Tatevossian Ruth G.³^ORCID,Jia Sujuan³,Campagne Olivia⁴,Sykes April²^ORCID,Stewart Clinton F.⁴^ORCID,Furman Wayne L.¹^ORCID,McGregor Lisa M.⁵

Affiliation:

1. Department of Oncology St. Jude Children's Research Hospital and Comprehensive Cancer Center Memphis Tennessee

2. Department of Biostatistics St. Jude Children's Research Hospital Memphis Tennessee

3. Diagnostic Biomarkers Shared Resource Department of Pathology St. Jude Children's Research Hospital Memphis Tennessee

4. Department of Pharmaceutical Sciences St. Jude Children's Research Hospital Memphis Tennessee

5. Department of Pediatrics Penn State University College of Medicine Hershey Pennsylvania

Funder

American Lebanese Syrian Associated Charities

Novartis

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32722

Reference31 articles.

1. The mTOR Signalling Pathway in Human Cancer

2. Current development of mTOR inhibitors as anticancer agents

3. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin‐like growth factor receptor;Dilling MB;Cancer Res,1994

4. CCI-779 Inhibits Rhabdomyosarcoma Xenograft Growth by an Antiangiogenic Mechanism Linked to the Targeting of mTOR/Hif-1α/VEGF Signaling

5. Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer;European Journal of Cancer;2024-08

2. Safety of Off-Label Use of Anticancer Drugs in Oncology;Creative surgery and oncology;2024-04-18

3. From bench to bedside: Advancing towards therapeutic treatment of vestibular schwannomas;Neuro-Oncology Advances;2024-01-01

4. New advances in the research of clinical treatment and novel anticancer agents in tumor angiogenesis;Biomedicine & Pharmacotherapy;2023-07

5. Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas;Current Oncology Reports;2023-03-18